Clinical Trial Update: Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System [EARLY_Phase 1]

View source ↗

Summary

An early-phase clinical trial is investigating CT103A cell therapy for relapsed/refractory antibody-associated inflammatory diseases of the nervous system. The …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autoimmune Encephalitis
• Idiopathic Inflammatory Myopathies
• Inflammatory Demyelinating Polyneuropathy
• Multiple Sclerosis
• Myasthenia Gravis
• Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
• Neuromyelitis Optica Spectrum Disorder
• Poems Syndrome

Drugs mentioned

• CT103A cells

Snippet

Sponsor: Tongji Hospital | Conditions: Autoimmune Diseases, Autoimmune Diseases of the Nervous System | EARLY_Phase 1 | Status: RECRUITING